Onconetix, Inc.

Onconetix, Inc.

Onconetix, Inc. is a publicly traded biotechnology firm with an integrated focus on oncology diagnostics and therapeutics. The company was formed through a reverse merger with ProPhase Labs' diagnostics subsidiary in 2023, a transaction that provided the operational infrastructure and public listing. Its wealth origin is traceable to the merger, with no single family or individual disclosed as the controlling owner. The firm's strategy spans two pillars: diagnostic products for cancer detection and therapeutic candidates for treatment. Its diagnostic portfolio includes the OncoTect product line, a molecular diagnostics platform for bladder cancer surveillance. On the therapeutic side, Onconetix holds rights to drugs targeting urothelial cancer and other solid tumors. The geographic footprint is primarily the United States, with no disclosed international operations. Onconetix does not publicly disclose total assets under management or team size. It maintains offices in New York, NY, and operates as a publicly reporting entity under SEC filings. A notable recent event was the October 2024 appointment of Dr. John A. Roberts as Chief Scientific Officer, as disclosed in a company press release. The firm's structural differentiator is its hybrid model combining diagnostic revenue with therapeutic R&D, an unusual structure that mirrors the convergence of detection and treatment in precision oncology. Its public-company status forces transparency on financial performance, a discipline absent in many privately held biotech firms.